Advanced Therapies Europe 2020

29TH - 30TH SEPTEMBER 2020


Phacilitate Leaders Europe Agenda


Plenary Discussion: Examining the shortages in manufacturing capacity - a global problem with local consequences

17 Sep 2019

This discussion will focus on:

  • Has the technology caught up to the speed of science?
  • Factors contributing to the capacity shortage
  • How does this impact cost overall?
  • Are we lacking technical expertise and talent?
  • Lack of available scale-up technology – impact on business in Europe
Ran Zheng, Chief Technical Officer - Orchard Therapeutics
Jan Thirkettle, Chief Development Officer - Freeline Tx
Alberto Santagostino, SVP of Head of Cell and Gene Technologies - Lonza
Troels Jordansen, CEO - Glycostem
Stephen Ward, Chief Manufacturing Officer - Cell and Gene Therapy Catapult
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd